Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2009, Article ID 672178, 6 pages
http://dx.doi.org/10.1155/2009/672178
Clinical Study

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema

1Department of Ophthalmology, Ospedali Riuniti, University of Foggia, Viale Pinto, 1 71100, Foggia, Italy
2Department of Hygiene, Policlinico di Bari, University of Bari, 70127 Bari, Italy

Received 19 August 2009; Accepted 2 December 2009

Academic Editor: Peter J. Francis

Copyright © 2009 G. Querques et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To report the outcomes after primary intravitreal pegaptanib sodium in patients with diabetic macular edema (DME). Methods. We conduced a retrospective analysis of eyes with DME treated with primary intravitreal pegaptanib sodium (Macugen) (intravitreal pegaptanib group). The results were compared with the ones of eyes treated with intravitreal pegaptanib sodium associated with macular laser photocoagulation (combined treatment group), and the ones of eyes treated with primary macular laser photocoagulation (macular laser photocoagulation group). Results. For the intravitreal pegaptanib group (13 eyes), we found significant changes in mean best-corrected visual acuity (BCVA) and reductions in mean central macular thickness (CMT) at the last follow-up visit ( 𝑃 = . 0 0 1 4 and 𝑃 = . 0 0 0 1 ). For the macular laser photocoagulation group (15 eyes), we found no statistically significant changes in mean BCVA and CMT at the last follow-up visit ( 𝑃 > . 0 5 ). For the combined treatment group (12 eyes), we found no significant changes in mean BCVA at the last follow-up visit ( 𝑃 > . 0 5 ) despite significant reductions in mean CMT ( 𝑃 = . 0 1 8 8 ). Conclusion. Intravitreal pegaptanib treatment alone may be superior to macular laser photocoagulation alone and to combined intravitreal pegaptanib treatment associated with macular laser photocoagulation in patients with DME.